[1] |
Smith SM, Milam PB, Fabbro SK, et al. Malignant intertrigo: a subset of toxic erythema of chemotherapy requiring recognition[J]. JAAD Case Rep, 2016,2(6):476⁃481. doi: 10.1016/j.jdcr. 2016.08.016.
|
[2] |
Kubicka⁃Wołkowska J, Kędzierska M, Lisik⁃Habib M, et al. Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: a case report and review of the literature[J]. Oncol Lett, 2016,12(6):5332⁃5334. doi: 10.3892/ol.2016.5309.
|
[3] |
Dai J, Micheletti R, Rosenbach M, et al. Striking follicular eruption to pegylated liposomal doxorubicin[J]. Am J Dermatopathol, 2014,36(7):590⁃591. doi: 10.1097/DAD.000000 0000000077.
|
[4] |
Totsuka M, Watanabe Y, Asai C, et al. Case of severe bullous erythema including intertrigo⁃like eruptions with angioedema induced by pegylated liposomal doxorubicin[J]. J Dermatol, 2019,46(6):535⁃539. doi: 10.1111/1346⁃8138.14895.
|
[5] |
Skelton H, Linstrum J, Smith K. Host⁃vs.⁃altered⁃host eruptions in patients on liposomal doxorubicin[J]. J Cutan Pathol, 2002,29(3):148⁃153. doi: 10.1034/j.1600⁃0560.2002.290304.x.
|
[6] |
Mangana J, Zipser MC, Conrad C, et al. Skin problems associated with pegylated liposomal doxorubicin⁃more than palmoplantar erythrodysesthesia syndrome[J]. Eur J Dermatol, 2008,18(5):566⁃570. doi: 10.1684/ejd.2008.0490.
|
[7] |
Najem A, Deregnaucourt D, Ramdane S, et al. Intertrigo⁃like dermatitis with pegylated liposomal doxorubicin: diagnosis and management[J]. J Clin Oncol, 2014,32(31):e104⁃e106. doi: 10. 1200/JCO.2013.48.7470.
|
[8] |
Campanelli A, Kerl K, Lübbe J. Severe palmoplantar erythrodysesthesia and intertrigolike eruption induced by polyethylene glycol⁃coated liposomal doxorubicin[J]. J Eur Acad Dermatol Venereol, 2006,20(8):1022⁃1024. doi: 10.1111/j.1468⁃3083.2006.01616.x.
|
[9] |
Yuan Y, Orlow SJ, Curtin J, et al. Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo[J]. Ecancermedicalscience, 2008,2:111. doi: 10.3332/ecancer. 2008.111.
|
[10] |
Seghers AC, Tey HL, Tee SI, et al. Pegylated liposomal doxorubicin⁃induced miliaria crystallina and lichenoid follicular eruption[J]. Indian J Dermatol Venereol Leprol, 2018,84(1):121. doi: 10.4103/0378⁃6323.206233.
|
[11] |
Richards KN, Stone RL, Rashid RM, et al. Dermatologic toxicity in a patient receiving liposomal doxorubicin[J]. Cutis, 2015,95(2):E10⁃E11.
|
[12] |
Wolf R, Tüzün Y. Baboon syndrome and toxic erythema of chemotherapy: Fold (intertriginous) dermatoses[J]. Clin Dermatol, 2015,33(4):462⁃465. doi: 10.1016/j.clindermatol.2015.04.008.
|
[13] |
Tansini PB, Boff AL, Weber MB, et al. Familial "benign" pemphigus? Erythroderma and fatal outcome[J]. An Bras Dermatol, 2020,95(1):75⁃77. doi: 10.1016/j.abd.2019.02.006.
|
[14] |
Nelson CA, Stephen S, Ashchyan HJ, et al. Neutrophilic dermatoses: pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease[J]. J Am Acad Dermatol, 2018,79(6):987⁃1006. doi: 10.1016/j.jaad.2017.11.064.
|
[15] |
Yokomichi N, Nagasawa T, Coler⁃Reilly A, et al. Pathogenesis of hand⁃foot syndrome induced by PEG⁃modified liposomal doxorubicin[J]. Hum Cell, 2013,26(1):8⁃18. doi: 10.1007/s13577⁃012⁃0057⁃0.
|
[16] |
Miller KK, Gorcey L, McLellan BN. Chemotherapy⁃induced hand⁃foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management[J]. J Am Acad Dermatol, 2014,71(4):787⁃794. doi: 10.1016/j.jaad.2014. 03.019.
|
[17] |
Jacobi U, Waibler E, Schulze P, et al. Release of doxorubicin in sweat: first step to induce the palmar⁃plantar erythrodysesthesia syndrome?[J]. Ann Oncol, 2005,16(7):1210⁃1211. doi: 10. 1093/annonc/mdi204.
|